Empagliflozin in Patients with Chronic Kidney Disease

BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:N Engl J Med
Hauptverfasser: Herrington, William G., Staplin, Natalie, Wanner, Christoph, Green, Jennifer B., Hauske, Sibylle J., Emberson, Jonathan R., Preiss, David, Judge, Parminder, Mayne, Kaitlin J., Ng, Sarah Y.A., Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K., Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P., Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R., Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J., Baigent, Colin, Haynes, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2023
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614055/
https://ncbi.nlm.nih.gov/pubmed/36331190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2204233
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge